Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation
- PMID: 17611563
- DOI: 10.1038/sj.leu.2404828
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation
Similar articles
-
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29. Biol Blood Marrow Transplant. 2012. PMID: 21963618 Clinical Trial.
-
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.J Clin Oncol. 2005 Aug 20;23(24):5675-87. doi: 10.1200/JCO.2005.07.061. J Clin Oncol. 2005. PMID: 16110027
-
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086801
-
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.Curr Opin Oncol. 2007 Nov;19(6):660-6. doi: 10.1097/CCO.0b013e3282f0e188. Curr Opin Oncol. 2007. PMID: 17906468 Review.
-
Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Bone Marrow Transplant. 2008 Mar;41(5):415-23. doi: 10.1038/sj.bmt.1705975. Epub 2008 Jan 21. Bone Marrow Transplant. 2008. PMID: 18209726 Review.
Cited by
-
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.Ann Hematol. 2022 Jun;101(6):1321-1331. doi: 10.1007/s00277-022-04821-y. Epub 2022 Mar 29. Ann Hematol. 2022. PMID: 35352216
-
Treatment of AML Relapse After Allo-HCT.Front Oncol. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207. eCollection 2021. Front Oncol. 2021. PMID: 34976845 Free PMC article. Review.
-
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.Transplant Cell Ther. 2021 Nov;27(11):921.e1-921.e10. doi: 10.1016/j.jtct.2021.08.007. Epub 2021 Aug 14. Transplant Cell Ther. 2021. PMID: 34403791 Free PMC article.
-
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.Front Immunol. 2021 Apr 1;12:639217. doi: 10.3389/fimmu.2021.639217. eCollection 2021. Front Immunol. 2021. PMID: 33868266 Free PMC article.
-
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.J Clin Oncol. 2021 Feb 10;39(5):386-396. doi: 10.1200/JCO.20.01587. Epub 2021 Jan 12. J Clin Oncol. 2021. PMID: 33434062 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
